Toward the blood-borne mirnome of human diseases

Size: px
Start display at page:

Download "Toward the blood-borne mirnome of human diseases"

Transcription

1 Nature Methods Toward the blood-borne mirnome of human diseases Andreas Keller, Petra Leidinger, Andrea Bauer, Abdou ElSharawy, Jan Haas, Christina Backes, Anke Wendschlag, Nathalia Giese, Christine Tjaden, Katja Ott, Jens Werner, Thilo Hackert, Klemens Ruprecht, Hanno Huwer, Junko Huebers, Gunnar Jacobs, Philip Rosenstiel, Henrik Dommisch, Arne Schaefer, Joachim Müller-Quernheim, Bernd Wullich, Bastian Keck, Norbert Graf, Joerg Reichrath, Britta Vogel, Almut Nebel, Sven U Jager, Peer Staehler, Ioannis Amarantos, Valesca Boisguerin, Cord Staehler, Markus Beier, Matthias Scheffler, Markus W Büchler, Joerg Wischhusen, Sebastian F M Haeusler, Johannes Dietl, Sylvia Hofmann, Hans- Peter Lenhof, Stefan Schreiber, Hugo A Katus, Wolfgang Rottbauer, Benjamin Meder, Joerg D Hoheisel, Andre Franke & Eckart Meese Supplementary Figure 1 Supplementary Figure 2 Supplementary Figure 3 Supplementary Figure 4 Supplementary Figure 5 Supplementary Figure 6 Supplementary Table 1 Supplementary Table 2 Supplementary Table 3 Supplementary Table 4 Supplementary Table 5 Supplementary Table 6 Supplementary Table 7 Supplementary Table 8 Analysis of different control cohorts by Principal Component Analysis (PCA). Technical reproducibility of microarray data. Biological reproducibility of microarray data. Fold quotients for 45 deregulated mirnas analyzed both by qrt-pcr and microarrays. Accuracies of mirna based classifications shown as Box- Whisker plots. Examples for the classification performance and representative Disease Probability Plots (DPP). Analyzed diseases and controls. MiRNAs that were deregulated in at least six diseases. Deregulated mirna in specific diseases. Pathway analysis of the 62 mirnas that were deregulated in at least six diseases and the 121 mirnas that were not deregulated. Deregulated mirnas, which are in physical proximity to SNPs that were previously associated with diseases analyzed in this study. Separation between diseases and controls based on different subsets of mirnas. MiRNA expression analysis by qrt-pcr using SmartChip Real-Time PCR System (Wafergen). Summary of mirna validation.

2 Nature Methods reference number: NMETH-BC12369B Supplementary Information Supplementary Figure 1 Analysis of different control cohorts by Principal Component Analysis (PCA). PCA that allows for estimating the variance of data sets, was applied to the mirna pattern of the five different healthy control groups. The figure shows the plot of the first versus the second principal component of all control samples and was created using the prcomp and chplot R packages. The convex hulls and confidence ellipses of the five normal control groups, each represented by a different color, show similar profiles with the exception of one group (group 5) that includes only individuals between 95 and 105 years of age. 0

3 Supplementary Figure 2 Technical reproducibility of microarray data. Color-coded correlation matrix demonstrating technical reproducibility of mirna profiles obtained by the microarray platform. Measurements were repeated for four samples including RNA from human heart and human brain tissues (numbered one and two), and from two normal blood samples (numbered three and four). Yellow color indicates a high correlation and blue color a low correlation. This figure clearly shows that the differences between heart and brain tissue are by far larger than the differences between different control blood samples. 1

4 Supplementary Figure 3 Biological reproducibility of microarray data. Color-coded correlation matrix demonstrating biological reproducibility of mirna profiles obtained by the microarray platform. Measurements were repeated twice for blood samples from one healthy individual taken at three different time points during a day. Blood was drawn at 9 A.M. (time point 1), 12 noon (time point 2), and 3 P.M. (time point 3). Yellow color indicates a high correlation and blue color a low correlation. We found that mirna profiles across one day are very stable. Notably, the correlation among the three time points was not lower than the correlation among the technical replicates. 2

5 Supplementary Figure 4: Fold quotients for 45 deregulated mirnas analyzed both by qrt-pcr (y-axis) and microarrays (x-axis). The correlation between both technologies was The bisecting line is indicated. Only four pairs have not been successfully validated. 3

6 Supplementary Figure 5: Accuracies of mirna based classifications shown as Box-Whisker plots. The blot shows the accuracies that were obtained for the classification of all diseases by using a subset of only 2 mirnas, 10 mirnas and by using the number of mirnas required to obtain the best possible classification. As indicated a median accuracy of 80% is already reached by using 10 markers only. 4

7 Supplementary Figures 5 A-C: 5

8 Examples for the classification performance and representative Disease Probability Plots (DPP). The classification performance is displayed for melanoma versus healthy controls (A), for multiple sclerosis versus healthy controls (B), and for lung cancer versus COPD (C). In the left column, the x-axis indicates the sample number and the y-axis indicates the logarithmized probabilities for each sample to fall either in the disease class or in the control class; the horizontal dashed line denotes the classification threshold. Vertical dashed lines separate controls from patients samples. For melanoma (A) and multiple sclerosis (B) we used control samples of health donors collected by five different institutions and for lung cancer (C) we used samples of COPD patients. Circles indicate false positive and false negative predictions, respectively. The right column shows the DPPS for three representative patients with melanoma, multiple sclerosis, or lung cancer. The chance of each patient having one of the diseases analyzed is given in percent and indicated by an arrowhead. 6

9 Supplementary Table 1: Analyzed diseases and controls. Cancers are indicated in blue and non-malignant (mainly chronic inflammatory) diseases in red. Annotations in brackets refer to OMIM ID and ICD-10. micrornas were classified as significantly deregulated for Benjamini Hochberg adjusted t-test P < Group Number of samples Institution providing RNA Controls 70 All institutions Lung cancer (211980; C33,C34) 32 Saarland University Prostate cancer (176807; C61) 23 Saarland University Melanoma (155600; C43) 35 Saarland University Wilms tumors (194070; C64) 5 Saarland University Ovarian cancer (167000; C56, D27) 15 Julius-Maximilians-University Wuerzburg gastric cancers (137215; C16) 13 DKFZ / Heidelberg University Pancreatic ductal adenocarcinoma (260350; C25.3) 45 DKFZ / Heidelberg University Other pancr. tumors and diseases 48 DKFZ / Heidelberg University Pancreatitis (167800, ; K85, K86) 38 DKFZ / Heidelberg University Chronic Obstructive Pulmonary Disease (606963; J40-J44, J47) 24 Saarland University Periodontitis (170650, ; K05.4) 18 Christian-Albrechts-University Kiel Sarcoidosis (181000, ; D86) 45 Christian-Albrechts-University Kiel Acute myocardial infarction (608320; I21-I22) 20 Heidelberg University Multiple sclerosis (126200; G35) 23 Saarland University SUM 454 7

10 Supplementary Table 2: MiRNAs that were deregulated in at least six diseases. The mirnas were grouped according to the numbers of diseases for which a deregulated mirna was found. Magenta labeled mirnas are the 24 mirnas that were significantly deregulated in > 50 % of all diseases. For those 24 mirnas additional information is given. Numbers in brackets indicate the numbers of up- and down-regulations, respectively. mirnas Number of diseases % of all diseases % of all mirnas Function hsa-mir-320d (1, 10) deregulated in colon cancer stem cells hsa-mir-423-5p (3,6) differentially expressed in lupus nephritis across different racial groups and all specimen types tested (EBVtransformed B-cell lines and PBMCs) hsa-mir-146b-3p (2, 7) identified in mirna classifiers that may predict recurrence of localized stage I non-small cell lung cancer / upregulated in K-ras-mutated colorectal cancer samples / hsa-mir-532-3p (1, 8) - hsa-mir-107 (3,5) mirna-107 transcription is directly activated by p53. mirna-107 regulates two important regulators of G(1)/S progression, CDK6 and the RB-related 2 gene RBL2 (p130) / mir-107 expression tends to be lower relative to other mirnas as Alzheimer disease progresses / hsa-mir-320c (1,7) - hsa-mir-324-3p (1,7) - hsa-mir-148a (0,8) down-regulated in osteo-differentiated multipotent mesenchymal stromal cells hsa-mir-320a (2,6) MicroRNA 320a functions as a novel endogenous modulator of aquaporins 1 and 4 as well as a potential therapeutic target in cerebral ischemia. / down-regulated after osteogenic differentiation of human ligament fibroblasts induced by conditioned medium of osteoclastlike cells / hsa-mir-1256 (1,7) - hsa-mir-556-5p (0,7) down-regulated in primary squamous cell lung carcinoma specimens compared to matched normal lung tissue / deregulated in HCT-116 (wt-p53) and HCT-116 (null-p53) colon cancer cell lines, here decreasing p53 expression via sirna treatment significantly decreased hsa-mir-26a hsa-mir-26a (6,1) expression / hsa-mir-197 (1,6) significantly associated with pericellular fibrosis in nonalcoholic steatohepatitis patients hsa-mir-500* (1,6) - hsa-mir-1295 (1,6) - PMID hsa-mir-646 (1,6) hsa-mir-646/ak is a candidate predisposing copy number variants in familial and early-onset colorectal cancer patients hsa-mir-339-5p (1,6) MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis hsa-mir-550* (1,6) - hsa-let-7d (5,2) Low-level expression of micrornas let-7d and mir-205 are prognostic markers of head and neck squamous cell carcinoma hsa-mir-595 (4,3) hsa-mir-1301 (1,6) deregulated in malignant mesothelioma /up-regulated inwi-38 human fibroblasts from replicating to reversible and irreversible growth arrest states /

11 hsa-mir-26b (5,2) down-regulated in primary squamous cell lung carcinoma specimens compared to matched normal lung tissue hsa-mir-1305 (0,7) - hsa-mir-1913 (0,7) - hsa-mir-27a (4,2) hsa-mir-145 (6,0) hsa-mir-541 (0,6) hsa-mir-500 (4,2) hsa-mir-146b-5p (4,2) hsa-mir-378 (3,3) hsa-mir-1226* (1,5) hsa-mir-455-3p (1,5) hsa-mir-182 (4,2) hsa-mir-1826 (0,6) hsa-mir-604 (1,5) hsa-mir-217 (0,6) hsa-mir-1258 (6,0) hsa-mir-196a* (0,6) hsa-mir-144 (3,3) hsa-mir-593* (1,5) hsa-mir-363* (2,4) hsa-mir-103 (1,5) hsa-let-7g (5,1) hsa-mir-30e* (6,0) hsa-mir-513b (0,6) hsa-mir-214 (0,6) hsa-mir-584 (4,2) hsa-mir-454* (5,1) hsa-mir-566 (0,6) hsa-mir-24-2* (0,6) hsa-mir-342-3p (1,5) hsa-mir-125a-5p (6,0) hsa-mir-126* (6,0) hsa-mir-1266 (1,5) hsa-mir-720 (1,5) hsa-mir-564 (1,5) hsa-mir-192* (0,6) hsa-mir-16 (5,1) hsa-mir-367 (1,5) hsa-mir-574-5p (3,3) hsa-mir-1272 (0,6) hsa-mir-21* (0,6)

12 Supplementary Table 3: Deregulated mirna in specific diseases. The first column shows the total number of diseases for which a deregulated mirna was found. The second column shows the number of diseases for which a deregulated mirna was found. Significant deregulation of mirna is indicated by (1); the lack of deregulation is indicated by (0). mirnas that were listed as deregulated in tissue in the human mirna disease database (HMDD) are indicated in bold. lung cancer pancreatic cancer ducatal ovarian cancer prostate cancer wilms tumor other pancreatic tumors and diseases gastric cancers multiple sclerosis sarcoidosis peridontitis COPD acute myocardial infarction mirna sum melanoma pancreatitis hsa-mir- 320d hsa-mir p hsa-mir- 146b-3p hsa-mir p hsa-mir hsa-mir- 320c hsa-mir p hsa-mir- 148a hsa-mir- 320a hsa-mir hsa-mir p hsa-mir-26a hsa-mir hsa-mir- 500* hsa-mir hsa-mir hsa-mir p hsa-mir- 550* hsa-let-7d hsa-mir hsa-mir hsa-mir-26b hsa-mir hsa-mir missmatch blood and tissue 6 match blood and tissue 9 10

13 Supplementary Table 4: Pathway analysis of the 62 mirnas that were deregulated in at least six diseases and the 121 mirnas that were not deregulated. For each pathway, the number of expected and detected target genes and the respective p-value is provided. Pathways that include significantly more mirna targets than statistically expected are indicated in magenta and pathways that include significantly less mirna targets than statistically expected are indicated in turquoise. The latter pathways may be enriched for "non-targets" of the analyzed mirnas. Pathway analysis of the 62 mirnas that were deregulated in at least six diseases p-value Subcategory expected observed (fdr) enrichment Metabolic pathways for targets Pathways in cancer for targets Pyrimidine metabolism for targets Arginine and proline metabolism for targets Lysosome for targets Cell cycle for targets Sphingolipid metabolism for targets Fc epsilon RI signaling pathway for targets Purine metabolism for targets Olfactory transduction <0.001 for non targets Ribosome 18 2 <0.001 for non targets Systemic lupus erythematosus for non targets Cell adhesion molecules (CAMs) for non targets Taste transduction for non targets Pathway analysis of the 121 mirnas that were not deregulated in any disease p-value Subcategory expected observed (fdr) enrichment Olfactory transduction <0.001 for non targets Systemic lupus erythematosus for non targets Metabolism of xenobiotics by cytochrome P for non targets 11

14 Supplementary Table 5: Deregulated mirnas, which are in physical proximity to SNPs that were previously associated with diseases analyzed in this study. The distance between mirnas and SNPs is given in base pairs. Column four lists the associated disease for each deregulated mirna and column five the disease that was previously associated with one of the listed SNPs by genome wide association studies (gwas) mirna SNP distance (bp) mirna diseases gwas disease hsa-mir- Cardiac structure and 346 rs acute myocardial infarction function hsa-mir rs acute myocardial infarction Mean platelet volume hsa-mir- 214 rs melanoma AND tumor of stomach AND multiple sclerosis AND sarcoidosis AND COPD AND acute myocardial infarction Mean platelet volume hsa-mir- 148b rs prostate cancer AND sarcoidosis AND acute myocardial infarction Mean platelet volume hsa-mir- 644 rs melanomaand multiple sclerosis AND periodontitis Melanoma hsa-mir- 616 rs multiple sclerosis AND periodontitis Multiple sclerosis hsa-mir rs prostate cancer Multiple sclerosis 12

15 Supplementary Table 6: Separation between diseases and controls based on different subsets of mirnas. Classification results are given for subsets of mirnas that achieved the best results, for subsets of 2 mirnas and subsets of 10 mirnas. For the first classification values greater than are indicated in bold. Positive and Negative Predictive values are provided for a disease prevalence of 1 %. disease # of mirnas Accuracy Specificity Sensitivity PPV NPV lung cancer other pancreatic tumors and diseases pancreatitis ovarian cancer COPD pancreatic cancer ducatal tumor of stomach sarcoidosis prostate cancer accute myocardial infarction peridontitis multiple sclerosis melanoma disease # of mirnas Accuracy Specificity Sensitivity lung cancer other pancreatic tumors and diseases pancreatitis ovarian cancer COPD pancreatic cancer ducatal tumor of stomach sarcoidosis prostate cancer accute myocardial infarction peridontitis multiple sclerosis melanoma

16 disease # of mirnas Accuracy Specificity Sensitivity lung cancer other pancreatic tumors and diseases pancreatitis ovarian cancer COPD pancreatic cancer ducatal tumor of stomach sarcoidosis prostate cancer accute myocardial infarction peridontitis multiple sclerosis melanoma

17 Supplementary Table 7: MiRNA expression analysis by qrt-pcr using SmartChip Real-Time PCR System (Wafergen). Columns 1 lists the names of the samples and column 2 the names of the mirnas. qrt-pcr Ct (cycle threshold) values, and standard deviation of the Ct values (Ct SD) are given for each mirna. Disease Sample Primer Ct Ct SD lung L463 HSA-MIR cancer L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR

18 L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR

19 L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR-1271 NaN NaN L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR-1271 NaN NaN L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR-1271 NaN NaN L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR-1271 NaN NaN L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR-130B L469 HSA-MIR-130B L485 HSA-MIR-130B L490 HSA-MIR-130B L492 HSA-MIR-130B L503 HSA-MIR-130B L507 HSA-MIR-130B L508 HSA-MIR-130B L509 HSA-MIR-130B L513 HSA-MIR-130B

20 L517 HSA-MIR-130B L523 HSA-MIR-130B L524 HSA-MIR-130B L525 HSA-MIR-130B L536 HSA-MIR-130B L537 HSA-MIR-130B L577 HSA-MIR-130B L585 HSA-MIR-130B L586 HSA-MIR-130B L596 HSA-MIR-130B L605 HSA-MIR-130B L606 HSA-MIR-130B L633 HSA-MIR-130B L637 HSA-MIR-130B L642 HSA-MIR-130B L657 HSA-MIR-130B L662 HSA-MIR-130B L669 HSA-MIR-130B L672 HSA-MIR-130B L682 HSA-MIR-130B L701 HSA-MIR-130B L702 HSA-MIR-130B L703 HSA-MIR-130B L711 HSA-MIR-130B L723 HSA-MIR-130B L726 HSA-MIR-130B L731 HSA-MIR-130B L746 HSA-MIR-130B L747 HSA-MIR-130B L748 HSA-MIR-130B L749 HSA-MIR-130B L755 HSA-MIR-130B L756 HSA-MIR-130B L760 HSA-MIR-130B L463 HSA-MIR-181C L469 HSA-MIR-181C L485 HSA-MIR-181C L490 HSA-MIR-181C L492 HSA-MIR-181C L503 HSA-MIR-181C L507 HSA-MIR-181C L508 HSA-MIR-181C L509 HSA-MIR-181C L513 HSA-MIR-181C L517 HSA-MIR-181C L523 HSA-MIR-181C L524 HSA-MIR-181C L525 HSA-MIR-181C L536 HSA-MIR-181C L537 HSA-MIR-181C L577 HSA-MIR-181C

21 L585 HSA-MIR-181C L586 HSA-MIR-181C L596 HSA-MIR-181C L605 HSA-MIR-181C L606 HSA-MIR-181C L633 HSA-MIR-181C L637 HSA-MIR-181C L642 HSA-MIR-181C L657 HSA-MIR-181C L662 HSA-MIR-181C L669 HSA-MIR-181C L672 HSA-MIR-181C L682 HSA-MIR-181C L701 HSA-MIR-181C L702 HSA-MIR-181C L703 HSA-MIR-181C L711 HSA-MIR-181C L723 HSA-MIR-181C L726 HSA-MIR-181C L731 HSA-MIR-181C L746 HSA-MIR-181C L747 HSA-MIR-181C L748 HSA-MIR-181C L749 HSA-MIR-181C L755 HSA-MIR-181C L756 HSA-MIR-181C L760 HSA-MIR-181C L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR

22 L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR-193A-3P L469 HSA-MIR-193A-3P L485 HSA-MIR-193A-3P NaN NaN L490 HSA-MIR-193A-3P L492 HSA-MIR-193A-3P L503 HSA-MIR-193A-3P L507 HSA-MIR-193A-3P L508 HSA-MIR-193A-3P L509 HSA-MIR-193A-3P L513 HSA-MIR-193A-3P L517 HSA-MIR-193A-3P L523 HSA-MIR-193A-3P L524 HSA-MIR-193A-3P L525 HSA-MIR-193A-3P L536 HSA-MIR-193A-3P L537 HSA-MIR-193A-3P L577 HSA-MIR-193A-3P L585 HSA-MIR-193A-3P L586 HSA-MIR-193A-3P L596 HSA-MIR-193A-3P L605 HSA-MIR-193A-3P L606 HSA-MIR-193A-3P L633 HSA-MIR-193A-3P L637 HSA-MIR-193A-3P L642 HSA-MIR-193A-3P L657 HSA-MIR-193A-3P L662 HSA-MIR-193A-3P L669 HSA-MIR-193A-3P L672 HSA-MIR-193A-3P L682 HSA-MIR-193A-3P L701 HSA-MIR-193A-3P

23 L702 HSA-MIR-193A-3P L703 HSA-MIR-193A-3P L711 HSA-MIR-193A-3P L723 HSA-MIR-193A-3P L726 HSA-MIR-193A-3P L731 HSA-MIR-193A-3P L746 HSA-MIR-193A-3P L747 HSA-MIR-193A-3P L748 HSA-MIR-193A-3P L749 HSA-MIR-193A-3P L755 HSA-MIR-193A-3P L756 HSA-MIR-193A-3P L760 HSA-MIR-193A-3P L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR

24 L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR-26A L469 HSA-MIR-26A L485 HSA-MIR-26A L490 HSA-MIR-26A L492 HSA-MIR-26A L503 HSA-MIR-26A L507 HSA-MIR-26A L508 HSA-MIR-26A L509 HSA-MIR-26A L513 HSA-MIR-26A L517 HSA-MIR-26A L523 HSA-MIR-26A L524 HSA-MIR-26A L525 HSA-MIR-26A L536 HSA-MIR-26A L537 HSA-MIR-26A L577 HSA-MIR-26A L585 HSA-MIR-26A L586 HSA-MIR-26A L596 HSA-MIR-26A L605 HSA-MIR-26A L606 HSA-MIR-26A L633 HSA-MIR-26A L637 HSA-MIR-26A L642 HSA-MIR-26A L657 HSA-MIR-26A L662 HSA-MIR-26A L669 HSA-MIR-26A L672 HSA-MIR-26A L682 HSA-MIR-26A L701 HSA-MIR-26A L702 HSA-MIR-26A NaN NaN L703 HSA-MIR-26A L711 HSA-MIR-26A L723 HSA-MIR-26A L726 HSA-MIR-26A L731 HSA-MIR-26A L746 HSA-MIR-26A L747 HSA-MIR-26A L748 HSA-MIR-26A L749 HSA-MIR-26A L755 HSA-MIR-26A L756 HSA-MIR-26A L760 HSA-MIR-26A L463 HSA-MIR-324-3P

25 L469 HSA-MIR-324-3P L485 HSA-MIR-324-3P L490 HSA-MIR-324-3P L492 HSA-MIR-324-3P L503 HSA-MIR-324-3P L507 HSA-MIR-324-3P L508 HSA-MIR-324-3P L509 HSA-MIR-324-3P L513 HSA-MIR-324-3P L517 HSA-MIR-324-3P L523 HSA-MIR-324-3P L524 HSA-MIR-324-3P L525 HSA-MIR-324-3P L536 HSA-MIR-324-3P L537 HSA-MIR-324-3P L577 HSA-MIR-324-3P L585 HSA-MIR-324-3P L586 HSA-MIR-324-3P L596 HSA-MIR-324-3P L605 HSA-MIR-324-3P L606 HSA-MIR-324-3P L633 HSA-MIR-324-3P L637 HSA-MIR-324-3P L642 HSA-MIR-324-3P L657 HSA-MIR-324-3P L662 HSA-MIR-324-3P L669 HSA-MIR-324-3P L672 HSA-MIR-324-3P L682 HSA-MIR-324-3P L701 HSA-MIR-324-3P L702 HSA-MIR-324-3P L703 HSA-MIR-324-3P L711 HSA-MIR-324-3P L723 HSA-MIR-324-3P L726 HSA-MIR-324-3P L731 HSA-MIR-324-3P L746 HSA-MIR-324-3P L747 HSA-MIR-324-3P L748 HSA-MIR-324-3P L749 HSA-MIR-324-3P L755 HSA-MIR-324-3P L756 HSA-MIR-324-3P L760 HSA-MIR-324-3P L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR

26 L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR

27 L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR

28 L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR

29 L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR

30 L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR L760 HSA-MIR L463 HSA-MIR L469 HSA-MIR L485 HSA-MIR L490 HSA-MIR L492 HSA-MIR L503 HSA-MIR L507 HSA-MIR L508 HSA-MIR L509 HSA-MIR L513 HSA-MIR L517 HSA-MIR L523 HSA-MIR L524 HSA-MIR L525 HSA-MIR L536 HSA-MIR-874 NaN NaN L537 HSA-MIR L577 HSA-MIR L585 HSA-MIR L586 HSA-MIR L596 HSA-MIR L605 HSA-MIR L606 HSA-MIR L633 HSA-MIR L637 HSA-MIR L642 HSA-MIR L657 HSA-MIR L662 HSA-MIR L669 HSA-MIR L672 HSA-MIR L682 HSA-MIR L701 HSA-MIR L702 HSA-MIR L703 HSA-MIR-874 NaN NaN L711 HSA-MIR L723 HSA-MIR L726 HSA-MIR L731 HSA-MIR L746 HSA-MIR L747 HSA-MIR L748 HSA-MIR L749 HSA-MIR L755 HSA-MIR L756 HSA-MIR

31 L760 HSA-MIR L463 HSA-MIR-92A L469 HSA-MIR-92A L485 HSA-MIR-92A L490 HSA-MIR-92A L492 HSA-MIR-92A L503 HSA-MIR-92A L507 HSA-MIR-92A L508 HSA-MIR-92A L509 HSA-MIR-92A L513 HSA-MIR-92A L517 HSA-MIR-92A L523 HSA-MIR-92A L524 HSA-MIR-92A L525 HSA-MIR-92A L536 HSA-MIR-92A L537 HSA-MIR-92A L577 HSA-MIR-92A L585 HSA-MIR-92A L586 HSA-MIR-92A L596 HSA-MIR-92A L605 HSA-MIR-92A NaN NaN L606 HSA-MIR-92A L633 HSA-MIR-92A L637 HSA-MIR-92A L642 HSA-MIR-92A L657 HSA-MIR-92A L662 HSA-MIR-92A L669 HSA-MIR-92A L672 HSA-MIR-92A L682 HSA-MIR-92A L701 HSA-MIR-92A L702 HSA-MIR-92A L703 HSA-MIR-92A L711 HSA-MIR-92A L723 HSA-MIR-92A L726 HSA-MIR-92A L731 HSA-MIR-92A L746 HSA-MIR-92A L747 HSA-MIR-92A L748 HSA-MIR-92A L749 HSA-MIR-92A L755 HSA-MIR-92A L756 HSA-MIR-92A L760 HSA-MIR-92A L463 HSA-MIR-93* L469 HSA-MIR-93* L485 HSA-MIR-93* L490 HSA-MIR-93* L492 HSA-MIR-93* NaN NaN L503 HSA-MIR-93*

32 L507 HSA-MIR-93* L508 HSA-MIR-93* L509 HSA-MIR-93* L513 HSA-MIR-93* L517 HSA-MIR-93* L523 HSA-MIR-93* L524 HSA-MIR-93* L525 HSA-MIR-93* L536 HSA-MIR-93* L537 HSA-MIR-93* L577 HSA-MIR-93* L585 HSA-MIR-93* L586 HSA-MIR-93* L596 HSA-MIR-93* L605 HSA-MIR-93* L606 HSA-MIR-93* L633 HSA-MIR-93* L637 HSA-MIR-93* L642 HSA-MIR-93* L657 HSA-MIR-93* L662 HSA-MIR-93* L669 HSA-MIR-93* L672 HSA-MIR-93* L682 HSA-MIR-93* L701 HSA-MIR-93* L702 HSA-MIR-93* L703 HSA-MIR-93* L711 HSA-MIR-93* L723 HSA-MIR-93* L726 HSA-MIR-93* L731 HSA-MIR-93* L746 HSA-MIR-93* L747 HSA-MIR-93* L748 HSA-MIR-93* L749 HSA-MIR-93* L755 HSA-MIR-93* L756 HSA-MIR-93* L760 HSA-MIR-93* COPD VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR VK27 HSA-MIR

33 VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR

34 VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR-1271 NaN NaN VK27 HSA-MIR VK28 HSA-MIR-1271 NaN NaN VK29 HSA-MIR VK3 HSA-MIR-1271 NaN NaN VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR-1271 NaN NaN VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR

35 VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR-130B VK12 HSA-MIR-130B VK13 HSA-MIR-130B VK14 HSA-MIR-130B VK15 HSA-MIR-130B VK16 HSA-MIR-130B VK18 HSA-MIR-130B VK2 HSA-MIR-130B VK21 HSA-MIR-130B VK22 HSA-MIR-130B VK24 HSA-MIR-130B VK26 HSA-MIR-130B VK27 HSA-MIR-130B VK28 HSA-MIR-130B VK29 HSA-MIR-130B VK3 HSA-MIR-130B VK30 HSA-MIR-130B VK31 HSA-MIR-130B VK32 HSA-MIR-130B VK33 HSA-MIR-130B VK34 HSA-MIR-130B VK35 HSA-MIR-130B VK36 HSA-MIR-130B VK37 HSA-MIR-130B VK40 HSA-MIR-130B VK41 HSA-MIR-130B VK42 HSA-MIR-130B VK43 HSA-MIR-130B VK44 HSA-MIR-130B VK45 HSA-MIR-130B VK46 HSA-MIR-130B VK47 HSA-MIR-130B NaN NaN VK48 HSA-MIR-130B VK49 HSA-MIR-130B VK50 HSA-MIR-130B VK51 HSA-MIR-130B VK52 HSA-MIR-130B VK6 HSA-MIR-130B VK7 HSA-MIR-130B VK8 HSA-MIR-130B VK9 HSA-MIR-130B VK11 HSA-MIR-181C VK12 HSA-MIR-181C

36 VK13 HSA-MIR-181C VK14 HSA-MIR-181C VK15 HSA-MIR-181C VK16 HSA-MIR-181C VK18 HSA-MIR-181C VK2 HSA-MIR-181C VK21 HSA-MIR-181C VK22 HSA-MIR-181C VK24 HSA-MIR-181C VK26 HSA-MIR-181C VK27 HSA-MIR-181C VK28 HSA-MIR-181C VK29 HSA-MIR-181C VK3 HSA-MIR-181C VK30 HSA-MIR-181C VK31 HSA-MIR-181C VK32 HSA-MIR-181C VK33 HSA-MIR-181C VK34 HSA-MIR-181C VK35 HSA-MIR-181C VK36 HSA-MIR-181C VK37 HSA-MIR-181C VK40 HSA-MIR-181C VK41 HSA-MIR-181C VK42 HSA-MIR-181C VK43 HSA-MIR-181C VK44 HSA-MIR-181C VK45 HSA-MIR-181C VK46 HSA-MIR-181C VK47 HSA-MIR-181C VK48 HSA-MIR-181C VK49 HSA-MIR-181C VK50 HSA-MIR-181C VK51 HSA-MIR-181C VK52 HSA-MIR-181C VK6 HSA-MIR-181C VK7 HSA-MIR-181C VK8 HSA-MIR-181C VK9 HSA-MIR-181C VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR

37 VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR-193A-3P VK12 HSA-MIR-193A-3P VK13 HSA-MIR-193A-3P VK14 HSA-MIR-193A-3P VK15 HSA-MIR-193A-3P VK16 HSA-MIR-193A-3P VK18 HSA-MIR-193A-3P VK2 HSA-MIR-193A-3P VK21 HSA-MIR-193A-3P VK22 HSA-MIR-193A-3P VK24 HSA-MIR-193A-3P VK26 HSA-MIR-193A-3P VK27 HSA-MIR-193A-3P VK28 HSA-MIR-193A-3P VK29 HSA-MIR-193A-3P VK3 HSA-MIR-193A-3P VK30 HSA-MIR-193A-3P VK31 HSA-MIR-193A-3P VK32 HSA-MIR-193A-3P VK33 HSA-MIR-193A-3P VK34 HSA-MIR-193A-3P VK35 HSA-MIR-193A-3P

38 VK36 HSA-MIR-193A-3P VK37 HSA-MIR-193A-3P VK40 HSA-MIR-193A-3P VK41 HSA-MIR-193A-3P VK42 HSA-MIR-193A-3P VK43 HSA-MIR-193A-3P VK44 HSA-MIR-193A-3P VK45 HSA-MIR-193A-3P VK46 HSA-MIR-193A-3P VK47 HSA-MIR-193A-3P VK48 HSA-MIR-193A-3P VK49 HSA-MIR-193A-3P VK50 HSA-MIR-193A-3P VK51 HSA-MIR-193A-3P VK52 HSA-MIR-193A-3P VK6 HSA-MIR-193A-3P VK7 HSA-MIR-193A-3P VK8 HSA-MIR-193A-3P VK9 HSA-MIR-193A-3P VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR

39 VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR-26A VK12 HSA-MIR-26A VK13 HSA-MIR-26A VK14 HSA-MIR-26A VK15 HSA-MIR-26A VK16 HSA-MIR-26A VK18 HSA-MIR-26A VK2 HSA-MIR-26A VK21 HSA-MIR-26A VK22 HSA-MIR-26A VK24 HSA-MIR-26A VK26 HSA-MIR-26A VK27 HSA-MIR-26A VK28 HSA-MIR-26A NaN NaN VK29 HSA-MIR-26A NaN NaN VK3 HSA-MIR-26A VK30 HSA-MIR-26A VK31 HSA-MIR-26A VK32 HSA-MIR-26A VK33 HSA-MIR-26A VK34 HSA-MIR-26A VK35 HSA-MIR-26A VK36 HSA-MIR-26A VK37 HSA-MIR-26A VK40 HSA-MIR-26A VK41 HSA-MIR-26A VK42 HSA-MIR-26A VK43 HSA-MIR-26A VK44 HSA-MIR-26A VK45 HSA-MIR-26A VK46 HSA-MIR-26A VK47 HSA-MIR-26A VK48 HSA-MIR-26A VK49 HSA-MIR-26A VK50 HSA-MIR-26A VK51 HSA-MIR-26A VK52 HSA-MIR-26A VK6 HSA-MIR-26A VK7 HSA-MIR-26A VK8 HSA-MIR-26A VK9 HSA-MIR-26A VK11 HSA-MIR-324-3P

40 VK12 HSA-MIR-324-3P VK13 HSA-MIR-324-3P VK14 HSA-MIR-324-3P VK15 HSA-MIR-324-3P VK16 HSA-MIR-324-3P VK18 HSA-MIR-324-3P VK2 HSA-MIR-324-3P VK21 HSA-MIR-324-3P VK22 HSA-MIR-324-3P VK24 HSA-MIR-324-3P VK26 HSA-MIR-324-3P VK27 HSA-MIR-324-3P VK28 HSA-MIR-324-3P VK29 HSA-MIR-324-3P VK3 HSA-MIR-324-3P VK30 HSA-MIR-324-3P VK31 HSA-MIR-324-3P VK32 HSA-MIR-324-3P VK33 HSA-MIR-324-3P VK34 HSA-MIR-324-3P VK35 HSA-MIR-324-3P VK36 HSA-MIR-324-3P VK37 HSA-MIR-324-3P VK40 HSA-MIR-324-3P VK41 HSA-MIR-324-3P VK42 HSA-MIR-324-3P VK43 HSA-MIR-324-3P VK44 HSA-MIR-324-3P VK45 HSA-MIR-324-3P VK46 HSA-MIR-324-3P VK47 HSA-MIR-324-3P VK48 HSA-MIR-324-3P VK49 HSA-MIR-324-3P VK50 HSA-MIR-324-3P VK51 HSA-MIR-324-3P VK52 HSA-MIR-324-3P VK6 HSA-MIR-324-3P VK7 HSA-MIR-324-3P VK8 HSA-MIR-324-3P VK9 HSA-MIR-324-3P VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR

41 VK26 HSA-MIR VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR

42 VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR

43 VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR

44 VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR VK24 HSA-MIR VK26 HSA-MIR VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR VK12 HSA-MIR VK13 HSA-MIR VK14 HSA-MIR VK15 HSA-MIR VK16 HSA-MIR VK18 HSA-MIR VK2 HSA-MIR VK21 HSA-MIR VK22 HSA-MIR

45 VK24 HSA-MIR VK26 HSA-MIR VK27 HSA-MIR VK28 HSA-MIR VK29 HSA-MIR VK3 HSA-MIR VK30 HSA-MIR VK31 HSA-MIR VK32 HSA-MIR VK33 HSA-MIR VK34 HSA-MIR VK35 HSA-MIR VK36 HSA-MIR VK37 HSA-MIR VK40 HSA-MIR VK41 HSA-MIR VK42 HSA-MIR VK43 HSA-MIR VK44 HSA-MIR VK45 HSA-MIR VK46 HSA-MIR VK47 HSA-MIR VK48 HSA-MIR VK49 HSA-MIR VK50 HSA-MIR VK51 HSA-MIR VK52 HSA-MIR VK6 HSA-MIR VK7 HSA-MIR VK8 HSA-MIR VK9 HSA-MIR VK11 HSA-MIR-92A VK12 HSA-MIR-92A VK13 HSA-MIR-92A VK14 HSA-MIR-92A VK15 HSA-MIR-92A VK16 HSA-MIR-92A VK18 HSA-MIR-92A VK2 HSA-MIR-92A VK21 HSA-MIR-92A VK22 HSA-MIR-92A VK24 HSA-MIR-92A VK26 HSA-MIR-92A NaN NaN VK27 HSA-MIR-92A VK28 HSA-MIR-92A VK29 HSA-MIR-92A VK3 HSA-MIR-92A VK30 HSA-MIR-92A VK31 HSA-MIR-92A VK32 HSA-MIR-92A VK33 HSA-MIR-92A

46 VK34 HSA-MIR-92A VK35 HSA-MIR-92A VK36 HSA-MIR-92A VK37 HSA-MIR-92A VK40 HSA-MIR-92A VK41 HSA-MIR-92A VK42 HSA-MIR-92A VK43 HSA-MIR-92A VK44 HSA-MIR-92A VK45 HSA-MIR-92A VK46 HSA-MIR-92A VK47 HSA-MIR-92A VK48 HSA-MIR-92A VK49 HSA-MIR-92A VK50 HSA-MIR-92A VK51 HSA-MIR-92A VK52 HSA-MIR-92A VK6 HSA-MIR-92A VK7 HSA-MIR-92A VK8 HSA-MIR-92A VK9 HSA-MIR-92A VK11 HSA-MIR-93* VK12 HSA-MIR-93* VK13 HSA-MIR-93* VK14 HSA-MIR-93* VK15 HSA-MIR-93* VK16 HSA-MIR-93* VK18 HSA-MIR-93* VK2 HSA-MIR-93* VK21 HSA-MIR-93* VK22 HSA-MIR-93* VK24 HSA-MIR-93* VK26 HSA-MIR-93* VK27 HSA-MIR-93* VK28 HSA-MIR-93* VK29 HSA-MIR-93* VK3 HSA-MIR-93* VK30 HSA-MIR-93* VK31 HSA-MIR-93* VK32 HSA-MIR-93* VK33 HSA-MIR-93* VK34 HSA-MIR-93* VK35 HSA-MIR-93* VK36 HSA-MIR-93* VK37 HSA-MIR-93* VK40 HSA-MIR-93* VK41 HSA-MIR-93* VK42 HSA-MIR-93* VK43 HSA-MIR-93* VK44 HSA-MIR-93* VK45 HSA-MIR-93*

47 VK46 HSA-MIR-93* VK47 HSA-MIR-93* VK48 HSA-MIR-93* VK49 HSA-MIR-93* VK50 HSA-MIR-93* VK51 HSA-MIR-93* VK52 HSA-MIR-93* VK6 HSA-MIR-93* VK7 HSA-MIR-93* VK8 HSA-MIR-93* VK9 HSA-MIR-93*

48 Supplemental Table 8: Summary of mirna validation. The table lists whether technical or biological validation has been performed (indicated by an X), shows the number of analyzed blood samples, and provides the fold change identified by either array or qrt-pcr analysis. Overview Publication (PMID) mirna condition Technical Validation Biological Validation hsa-mir-1260 lung diseases x x 85 hsa-mir-484 lung diseases x x 85 hsa-mir-92a lung diseases x x 85 hsa-mir-183 lung diseases x x 85 hsa-mir-25 lung diseases x x 85 hsa-mir-324-3p lung diseases x x 85 hsa-mir-126 lung diseases x x 85 hsa-mir-328 lung diseases x x 85 hsa-mir-363 lung diseases x x 85 hsa-mir-636 lung diseases x x 85 hsa-mir-93* lung diseases x x 85 hsa-mir-26a lung diseases x x 85 hsa-mir-627 lung diseases x x 85 hsa-mir-130b lung diseases x x 85 hsa-mir-874 lung diseases x x 85 hsa-mir-1271 lung diseases x x 85 hsa-mir-181c lung diseases x x 85 hsa-mir-193a-3p lung diseases x x hsa-mir-140-3p lung cancer x hsa-mir-22 lung cancer x hsa-let7d lung cancer x hsa-mir-106b lung cancer x hsa-mir-98 lung cancer x hsa-mir-126 lung cancer x hsa-let7c multiple sclerosis x hsa-mir-233 multiple sclerosis x hsa-mir-106b melanoma x hsa-mir-107 melanoma x hsa-mir-1280 melanoma x hsa-mir-151-3p melanoma x hsa-mir-17* melanoma x hsa-mir-18a melanoma x hsa-mir-199a-5p melanoma x hsa-mir-20a melanoma x hsa-mir-20b melanoma x hsa-mir-30a melanoma x hsa-mir-362-3p melanoma x hsa-mir-550* melanoma x hsa-mir-664 melanoma x - 20 #Samples 46

49 hsa-mir-128 glioblastoma - x hsa-mir-342-3p glioblastoma - x mir-455-3p acute myocardial infarction x mir-10b* acute myocardial infarction x mir-216a acute myocardial infarction x mir-1291 acute myocardial infarction x - 20 All details Publication (pmid) mirna condition Technical Validation Biological Validation #Samples fold change array hsa-let7c multiple sclerosis x hsa-let7d lung cancer x hsa-mir-106b lung cancer x hsa-mir-106b melanoma x hsa-mir-107 melanoma x hsa-mir-10b* Acute Myocardial Inf. x hsa-mir-126 lung diseases x x hsa-mir-126 lung cancer x hsa-mir-1260 lung diseases x x hsa-mir-1271 lung diseases x x hsa-mir-128 glioblastoma - x hsa-mir-1280 melanoma x hsa-mir-1291 Acute Myocardial Inf. x hsa-mir-130b lung diseases x x hsa-mir-140-3p lung cancer x hsa-mir-151-3p melanoma x hsa-mir-17* melanoma x hsa-mir-181c lung diseases x x hsa-mir-183 lung diseases x x hsa-mir-18a melanoma x hsa-mir-193a-3p lung diseases x x hsa-mir-199a-5p melanoma x hsa-mir-20a melanoma x hsa-mir-20b melanoma x hsa-mir-216a Acute Myocardial Inf. x hsa-mir-22 lung cancer x hsa-mir-233 multiple sclerosis x hsa-mir-25 lung diseases x x hsa-mir-26a lung diseases x x hsa-mir-30a melanoma x hsa-mir-324-3p lung diseases x x hsa-mir-328 lung diseases x x hsa-mir-342-3p glioblastoma - x hsa-mir-362-3p melanoma x hsa-mir-363 lung diseases x x hsa-mir-455-3p Acute Myocardial Inf. x hsa-mir-484 lung diseases x x hsa-mir-550* melanoma x hsa-mir-627 lung diseases x x hsa-mir-636 lung diseases x x hsa-mir-664 melanoma x hsa-mir-874 lung diseases x x hsa-mir-92a lung diseases x x hsa-mir-93* lung diseases x x hsa-mir-98 lung cancer x fold change qrt_pcr Correlation

50 Lung diseases mirna fold change array fold change qrt_pcr hsa-mir hsa-mir hsa-mir-92a hsa-mir hsa-mir hsa-mir-324-3p hsa-mir hsa-mir hsa-mir hsa-mir hsa-mir-93* hsa-mir-26a hsa-mir hsa-mir-130b hsa-mir hsa-mir hsa-mir-181c hsa-mir-193a-3p

51 Lung cancer fold change array fold change qrt_pcr mirna hsa-mir-140-3p hsa-mir hsa-let7d hsa-mir-106b hsa-mir hsa-mir Multiple Sclerosis fold change array fold change qrt_pcr mirna let-7c mir

52 Melanoma mirna fold change array fold change qrt_pcr hsa-mir-106b hsa-mir hsa-mir hsa-mir-151-3p hsa-mir-17* hsa-mir-18a hsa-mir-199a-5p hsa-mir-20a hsa-mir-20b hsa-mir-30a hsa-mir-362-3p hsa-mir-550* hsa-mir Acute myocardial infarction fold change array fold change qrt_pcr mirna mir-455-3p mir-10b* mir-216a mir

mirnas can be generally associated with human pathologies as exemplified for mir-144*

mirnas can be generally associated with human pathologies as exemplified for mir-144* Keller et al. BMC Medicine 2014, 12:224 RESEARCH ARTICLE Open Access mirnas can be generally associated with human pathologies as exemplified for mir-144* Andreas Keller 1*, Petra Leidinger 2, Britta Vogel

More information

microrna PCR System (Exiqon), following the manufacturer s instructions. In brief, 10ng of

microrna PCR System (Exiqon), following the manufacturer s instructions. In brief, 10ng of SUPPLEMENTAL MATERIALS AND METHODS Quantitative RT-PCR Quantitative RT-PCR analysis was performed using the Universal mircury LNA TM microrna PCR System (Exiqon), following the manufacturer s instructions.

More information

Bootstrapped Integrative Hypothesis Test, COPD-Lung Cancer Differentiation, and Joint mirnas Biomarkers

Bootstrapped Integrative Hypothesis Test, COPD-Lung Cancer Differentiation, and Joint mirnas Biomarkers Bootstrapped Integrative Hypothesis Test, COPD-Lung Cancer Differentiation, and Joint mirnas Biomarkers Kai-Ming Jiang 1,2, Bao-Liang Lu 1,2, and Lei Xu 1,2,3(&) 1 Department of Computer Science and Engineering,

More information

Principal Component Analysis Based Feature Extraction Approach to Identify Circulating microrna Biomarkers

Principal Component Analysis Based Feature Extraction Approach to Identify Circulating microrna Biomarkers Principal Component Analysis Based Feature Extraction Approach to Identify Circulating microrna Biomarkers Y-h. Taguchi 1 *, Yoshiki Murakami 2 1 Department of Physics, Chuo University, Tokyo, Japan, 2

More information

Supplementary Figures

Supplementary Figures Supplementary Figures Supplementary Figure 1. Heatmap of GO terms for differentially expressed genes. The terms were hierarchically clustered using the GO term enrichment beta. Darker red, higher positive

More information

microrna Presented for: Presented by: Date:

microrna Presented for: Presented by: Date: microrna Presented for: Presented by: Date: 2 micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved Regulate gene expression by binding complementary regions at 3 regions

More information

Figure S1. Analysis of endo-sirna targets in different microarray datasets. The

Figure S1. Analysis of endo-sirna targets in different microarray datasets. The Supplemental Figures: Figure S1. Analysis of endo-sirna targets in different microarray datasets. The percentage of each array dataset that were predicted endo-sirna targets according to the Ambros dataset

More information

Profiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola

Profiles of gene expression & diagnosis/prognosis of cancer. MCs in Advanced Genetics Ainoa Planas Riverola Profiles of gene expression & diagnosis/prognosis of cancer MCs in Advanced Genetics Ainoa Planas Riverola Gene expression profiles Gene expression profiling Used in molecular biology, it measures the

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:10.1038/nature10866 a b 1 2 3 4 5 6 7 Match No Match 1 2 3 4 5 6 7 Turcan et al. Supplementary Fig.1 Concepts mapping H3K27 targets in EF CBX8 targets in EF H3K27 targets in ES SUZ12 targets in ES

More information

Nature Getetics: doi: /ng.3471

Nature Getetics: doi: /ng.3471 Supplementary Figure 1 Summary of exome sequencing data. ( a ) Exome tumor normal sample sizes for bladder cancer (BLCA), breast cancer (BRCA), carcinoid (CARC), chronic lymphocytic leukemia (CLLX), colorectal

More information

ARTICLE RESEARCH. Macmillan Publishers Limited. All rights reserved

ARTICLE RESEARCH. Macmillan Publishers Limited. All rights reserved Extended Data Figure 6 Annotation of drivers based on clinical characteristics and co-occurrence patterns. a, Putative drivers affecting greater than 10 patients were assessed for enrichment in IGHV mutated

More information

a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation,

a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation, Supplementary Information Supplementary Figures Supplementary Figure 1. a) List of KMTs targeted in the shrna screen. The official symbol, KMT designation, gene ID and specifities are provided. Those highlighted

More information

Gene-microRNA network module analysis for ovarian cancer

Gene-microRNA network module analysis for ovarian cancer Gene-microRNA network module analysis for ovarian cancer Shuqin Zhang School of Mathematical Sciences Fudan University Oct. 4, 2016 Outline Introduction Materials and Methods Results Conclusions Introduction

More information

SUPPLEMENTARY APPENDIX

SUPPLEMENTARY APPENDIX SUPPLEMENTARY APPENDIX 1) Supplemental Figure 1. Histopathologic Characteristics of the Tumors in the Discovery Cohort 2) Supplemental Figure 2. Incorporation of Normal Epidermal Melanocytic Signature

More information

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute

Whole Genome and Transcriptome Analysis of Anaplastic Meningioma. Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Whole Genome and Transcriptome Analysis of Anaplastic Meningioma Patrick Tarpey Cancer Genome Project Wellcome Trust Sanger Institute Outline Anaplastic meningioma compared to other cancers Whole genomes

More information

Supplementary information to:

Supplementary information to: Supplementary information to: Digital Sorting of Pure Cell Populations Enables Unambiguous Genetic Analysis of Heterogeneous Formalin-Fixed Paraffin Embedded Tumors by Next Generation Sequencing Authors

More information

developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success

developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success micrornas developing new tools for diagnostics Join forces with IMGM Laboratories to make your mirna project a success Dr. Carola Wagner IMGM Laboratories GmbH Martinsried, Germany qpcr 2009 Symposium

More information

Nature Medicine: doi: /nm.3967

Nature Medicine: doi: /nm.3967 Supplementary Figure 1. Network clustering. (a) Clustering performance as a function of inflation factor. The grey curve shows the median weighted Silhouette widths for varying inflation factors (f [1.6,

More information

Supplementary Material

Supplementary Material Supplementary Material Identification of mir-187 and mir-182 as biomarkers for early diagnosis and prognosis in prostate cancer patients treated with radical prostatectomy Irene Casanova-Salas 1, José

More information

COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION

COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION COMPUTATIONAL OPTIMISATION OF TARGETED DNA SEQUENCING FOR CANCER DETECTION Pierre Martinez, Nicholas McGranahan, Nicolai Juul Birkbak, Marco Gerlinger, Charles Swanton* SUPPLEMENTARY INFORMATION SUPPLEMENTARY

More information

User s Manual Version 1.0

User s Manual Version 1.0 User s Manual Version 1.0 #639 Longmian Avenue, Jiangning District, Nanjing,211198,P.R.China. http://tcoa.cpu.edu.cn/ Contact us at xiaosheng.wang@cpu.edu.cn for technical issue and questions Catalogue

More information

Chromatin marks identify critical cell-types for fine-mapping complex trait variants

Chromatin marks identify critical cell-types for fine-mapping complex trait variants Chromatin marks identify critical cell-types for fine-mapping complex trait variants Gosia Trynka 1-4 *, Cynthia Sandor 1-4 *, Buhm Han 1-4, Han Xu 5, Barbara E Stranger 1,4#, X Shirley Liu 5, and Soumya

More information

Can melanoma treatment be guided by a panel of predictive and prognostic microrna Biomarkers?

Can melanoma treatment be guided by a panel of predictive and prognostic microrna Biomarkers? Can melanoma treatment be guided by a panel of predictive and prognostic microrna Biomarkers? Mitchell Stark Research Fellow Dermatology Research Centre WCCS2016 Vienna, Austria Survival is stage dependant

More information

Supplementary Figure 1

Supplementary Figure 1 Supplementary Figure 1 Asymmetrical function of 5p and 3p arms of mir-181 and mir-30 families and mir-142 and mir-154. (a) Control experiments using mirna sensor vector and empty pri-mirna overexpression

More information

Nature Genetics: doi: /ng Supplementary Figure 1. SEER data for male and female cancer incidence from

Nature Genetics: doi: /ng Supplementary Figure 1. SEER data for male and female cancer incidence from Supplementary Figure 1 SEER data for male and female cancer incidence from 1975 2013. (a,b) Incidence rates of oral cavity and pharynx cancer (a) and leukemia (b) are plotted, grouped by males (blue),

More information

MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL

MicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes

More information

Supplementary Materials for

Supplementary Materials for www.sciencesignaling.org/cgi/content/full/8/393/rs9/dc1 Supplementary Materials for Identification of potential drug targets for tuberous sclerosis complex by synthetic screens combining CRISPR-based knockouts

More information

Digitizing the Proteomes From Big Tissue Biobanks

Digitizing the Proteomes From Big Tissue Biobanks Digitizing the Proteomes From Big Tissue Biobanks Analyzing 24 Proteomes Per Day by Microflow SWATH Acquisition and Spectronaut Pulsar Analysis Jan Muntel 1, Nick Morrice 2, Roland M. Bruderer 1, Lukas

More information

Supplementary Tables. Supplementary Figures

Supplementary Tables. Supplementary Figures Supplementary Files for Zehir, Benayed et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients Supplementary Tables Supplementary Table 1: Sample

More information

Supporting Information

Supporting Information Supporting Information Retinal expression of small non-coding RNAs in a murine model of proliferative retinopathy Chi-Hsiu Liu 1, Zhongxiao Wang 1, Ye Sun 1, John Paul SanGiovanni 2, Jing Chen 1, * 1 Department

More information

Expanded View Figures

Expanded View Figures EMO Molecular Medicine Proteomic map of squamous cell carcinomas Hanibal ohnenberger et al Expanded View Figures Figure EV1. Technical reproducibility. Pearson s correlation analysis of normalised SILC

More information

microrna-200b and microrna-200c promote colorectal cancer cell proliferation via

microrna-200b and microrna-200c promote colorectal cancer cell proliferation via Supplementary Materials microrna-200b and microrna-200c promote colorectal cancer cell proliferation via targeting the reversion-inducing cysteine-rich protein with Kazal motifs Supplementary Table 1.

More information

IPA Advanced Training Course

IPA Advanced Training Course IPA Advanced Training Course October 2013 Academia sinica Gene (Kuan Wen Chen) IPA Certified Analyst Agenda I. Data Upload and How to Run a Core Analysis II. Functional Interpretation in IPA Hands-on Exercises

More information

Deploying the full transcriptome using RNA sequencing. Jo Vandesompele, CSO and co-founder The Non-Coding Genome May 12, 2016, Leuven

Deploying the full transcriptome using RNA sequencing. Jo Vandesompele, CSO and co-founder The Non-Coding Genome May 12, 2016, Leuven Deploying the full transcriptome using RNA sequencing Jo Vandesompele, CSO and co-founder The Non-Coding Genome May 12, 2016, Leuven Roadmap Biogazelle the power of RNA reasons to study non-coding RNA

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Microarray-based Gene Expression Testing for Cancers of Unknown File Name: Origination: Last CAP Review: Next CAP Review: Last Review: microarray-based_gene_expression_testing_for_cancers_of_unknown_primary

More information

7SK ChIRP-seq is specifically RNA dependent and conserved between mice and humans.

7SK ChIRP-seq is specifically RNA dependent and conserved between mice and humans. Supplementary Figure 1 7SK ChIRP-seq is specifically RNA dependent and conserved between mice and humans. Regions targeted by the Even and Odd ChIRP probes mapped to a secondary structure model 56 of the

More information

A novel and universal method for microrna RT-qPCR data normalization

A novel and universal method for microrna RT-qPCR data normalization A novel and universal method for microrna RT-qPCR data normalization Jo Vandesompele professor, Ghent University co-founder and CEO, Biogazelle 4 th International qpcr Symposium Weihenstephan, March 1,

More information

SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer.

SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer. Supplementary Figure 1 SSM signature genes are highly expressed in residual scar tissues after preoperative radiotherapy of rectal cancer. Scatter plots comparing expression profiles of matched pretreatment

More information

Supplementary Figure 1: LUMP Leukocytes unmethylabon to infer tumor purity

Supplementary Figure 1: LUMP Leukocytes unmethylabon to infer tumor purity Supplementary Figure 1: LUMP Leukocytes unmethylabon to infer tumor purity A Consistently unmethylated sites (30%) in 21 cancer types 174,696

More information

Case Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD

Case Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD Case Studies on High Throughput Gene Expression Data Kun Huang, PhD Raghu Machiraju, PhD Department of Biomedical Informatics Department of Computer Science and Engineering The Ohio State University Review

More information

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization

More information

Supplementary information for: Human micrornas co-silence in well-separated groups and have different essentialities

Supplementary information for: Human micrornas co-silence in well-separated groups and have different essentialities Supplementary information for: Human micrornas co-silence in well-separated groups and have different essentialities Gábor Boross,2, Katalin Orosz,2 and Illés J. Farkas 2, Department of Biological Physics,

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION DOI:.38/ncb3399 a b c d FSP DAPI 5mm mm 5mm 5mm e Correspond to melanoma in-situ Figure a DCT FSP- f MITF mm mm MlanaA melanoma in-situ DCT 5mm FSP- mm mm mm mm mm g melanoma in-situ MITF MlanaA mm mm

More information

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA

Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) cancer DNA www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Single-strand DNA library preparation improves sequencing of formalin-fixed and paraffin-embedded (FFPE) DNA Supplementary Materials

More information

No evidence of clonally selected somatic genomic alterations in cancer associated

No evidence of clonally selected somatic genomic alterations in cancer associated Supplementary Data Resource No evidence of clonally selected somatic genomic alterations in cancer associated fibroblasts from human breast and ovarian carcinomas Wen Qiu, Min Hu, Anita Sridhar, Ken Opeskin,

More information

Title: Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles

Title: Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles Author's response to reviews Title: Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles Authors: Julia Tchou (julia.tchou@uphs.upenn.edu) Andrew V Kossenkov (akossenkov@wistar.org)

More information

Nature Methods: doi: /nmeth.3115

Nature Methods: doi: /nmeth.3115 Supplementary Figure 1 Analysis of DNA methylation in a cancer cohort based on Infinium 450K data. RnBeads was used to rediscover a clinically distinct subgroup of glioblastoma patients characterized by

More information

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION doi:.38/nature8975 SUPPLEMENTAL TEXT Unique association of HOTAIR with patient outcome To determine whether the expression of other HOX lincrnas in addition to HOTAIR can predict patient outcome, we measured

More information

Gene Ontology 2 Function/Pathway Enrichment. Biol4559 Thurs, April 12, 2018 Bill Pearson Pinn 6-057

Gene Ontology 2 Function/Pathway Enrichment. Biol4559 Thurs, April 12, 2018 Bill Pearson Pinn 6-057 Gene Ontology 2 Function/Pathway Enrichment Biol4559 Thurs, April 12, 2018 Bill Pearson wrp@virginia.edu 4-2818 Pinn 6-057 Function/Pathway enrichment analysis do sets (subsets) of differentially expressed

More information

Cellecta Overview. Started Operations in 2007 Headquarters: Mountain View, CA

Cellecta Overview. Started Operations in 2007 Headquarters: Mountain View, CA Cellecta Overview Started Operations in 2007 Headquarters: Mountain View, CA Focus: Development of flexible, scalable, and broadly parallel genetic screening assays to expedite the discovery and characterization

More information

Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded

Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded Supplementary Figure 1. Metabolic landscape of cancer discovery pipeline. RNAseq raw counts data of cancer and healthy tissue samples were downloaded from TCGA and differentially expressed metabolic genes

More information

Supplemental Figure S1. Expression of Cirbp mrna in mouse tissues and NIH3T3 cells.

Supplemental Figure S1. Expression of Cirbp mrna in mouse tissues and NIH3T3 cells. SUPPLEMENTAL FIGURE AND TABLE LEGENDS Supplemental Figure S1. Expression of Cirbp mrna in mouse tissues and NIH3T3 cells. A) Cirbp mrna expression levels in various mouse tissues collected around the clock

More information

Patnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies

Patnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies Patnaik SK, et al. MicroRNAs to accurately histotype NSCLC biopsies. 2014. Supplemental Digital Content 1. Appendix 1. External data-sets used for associating microrna expression with lung squamous cell

More information

mirna Biomarkers Seena K. Ajit PhD Pharmacology & Physiology Drexel University College of Medicine October 12, 2017

mirna Biomarkers Seena K. Ajit PhD Pharmacology & Physiology Drexel University College of Medicine October 12, 2017 mirna Biomarkers Seena K. Ajit PhD Pharmacology & Physiology Drexel University College of Medicine October 12, 2017 Outline Introduction Circulating mirnas as potential biomarkers for pain Complex regional

More information

Session 4 Rebecca Poulos

Session 4 Rebecca Poulos The Cancer Genome Atlas (TCGA) & International Cancer Genome Consortium (ICGC) Session 4 Rebecca Poulos Prince of Wales Clinical School Introductory bioinformatics for human genomics workshop, UNSW 20

More information

BMC Cancer. Open Access. Abstract. BioMed Central

BMC Cancer. Open Access. Abstract. BioMed Central BMC Cancer BioMed Central Research article mirnas in lung cancer - Studying complex fingerprints in patient's blood cells by microarray experiments Andreas Keller* 1, Petra Leidinger 2, Anne Borries 1,

More information

Table S1: Analysis of Notch gene rearrangements in triple negative breast cancer subtypes

Table S1: Analysis of Notch gene rearrangements in triple negative breast cancer subtypes Supplemental Tables Table S1: Analysis of Notch gene rearrangements in triple negative breast cancer subtypes NOTCH1 or NOTCH2 Basal Immune Luminal AR Mesenchymal Stem Like WT 27 (87%) 24 (100%) 4 (66%)

More information

RASA: Robust Alternative Splicing Analysis for Human Transcriptome Arrays

RASA: Robust Alternative Splicing Analysis for Human Transcriptome Arrays Supplementary Materials RASA: Robust Alternative Splicing Analysis for Human Transcriptome Arrays Junhee Seok 1*, Weihong Xu 2, Ronald W. Davis 2, Wenzhong Xiao 2,3* 1 School of Electrical Engineering,

More information

A two-microrna signature in urinary exosomes for diagnosis of prostate cancer

A two-microrna signature in urinary exosomes for diagnosis of prostate cancer Poster # B4 A two-microrna signature in urinary exosomes for diagnosis of prostate cancer Anne Karin Ildor Rasmussen 1, Peter Mouritzen 1, Karina Dalsgaard Sørensen 3, Thorarinn Blondal 1, Jörg Krummheuer

More information

RNA preparation from extracted paraffin cores:

RNA preparation from extracted paraffin cores: Supplementary methods, Nielsen et al., A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor positive breast cancer.

More information

Nature Immunology: doi: /ni Supplementary Figure 1. RNA-Seq analysis of CD8 + TILs and N-TILs.

Nature Immunology: doi: /ni Supplementary Figure 1. RNA-Seq analysis of CD8 + TILs and N-TILs. Supplementary Figure 1 RNA-Seq analysis of CD8 + TILs and N-TILs. (a) Schematic representation of the tumor and cell types used for the study. HNSCC, head and neck squamous cell cancer; NSCLC, non-small

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Leiter U, Stadler R, Mauch C, et al, for the

More information

Statistics and Epidemiology Practice Questions

Statistics and Epidemiology Practice Questions 1. Which of the following is not considered a measure of central tendency? a. Median b. Range c. Mode d. Average 2. Given the following set of values, what is the median? 4 5 9 3 8 3 7 1 5 3 a. 3 b. 5

More information

Nature Genetics: doi: /ng Supplementary Figure 1

Nature Genetics: doi: /ng Supplementary Figure 1 Supplementary Figure 1 Replicability of blood eqtl effects in ileal biopsies from the RISK study. eqtls detected in the vicinity of SNPs associated with IBD tend to show concordant effect size and direction

More information

Soft Agar Assay. For each cell pool, 100,000 cells were resuspended in 0.35% (w/v)

Soft Agar Assay. For each cell pool, 100,000 cells were resuspended in 0.35% (w/v) SUPPLEMENTARY MATERIAL AND METHODS Soft Agar Assay. For each cell pool, 100,000 cells were resuspended in 0.35% (w/v) top agar (LONZA, SeaKem LE Agarose cat.5004) and plated onto 0.5% (w/v) basal agar.

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the

More information

Supplementary Figure 1: High-throughput profiling of survival after exposure to - radiation. (a) Cells were plated in at least 7 wells in a 384-well

Supplementary Figure 1: High-throughput profiling of survival after exposure to - radiation. (a) Cells were plated in at least 7 wells in a 384-well Supplementary Figure 1: High-throughput profiling of survival after exposure to - radiation. (a) Cells were plated in at least 7 wells in a 384-well plate at cell densities ranging from 25-225 cells in

More information

High AU content: a signature of upregulated mirna in cardiac diseases

High AU content: a signature of upregulated mirna in cardiac diseases https://helda.helsinki.fi High AU content: a signature of upregulated mirna in cardiac diseases Gupta, Richa 2010-09-20 Gupta, R, Soni, N, Patnaik, P, Sood, I, Singh, R, Rawal, K & Rani, V 2010, ' High

More information

Supplementary Materials for

Supplementary Materials for www.sciencesignaling.org/cgi/content/full/7/310/ra11/dc1 Supplementary Materials for STAT3 Induction of mir-146b Forms a Feedback Loop to Inhibit the NF-κB to IL-6 Signaling Axis and STAT3-Driven Cancer

More information

Supplementary Information

Supplementary Information Supplementary Information Supplementary Figure 1. Western blotting with ERβ antibodies Full blots corresponding to Fig. 2, along with replicated experiments at different time points, different batches,

More information

Supplementary information. Supplementary figure 1. Flow chart of study design

Supplementary information. Supplementary figure 1. Flow chart of study design Supplementary information Supplementary figure 1. Flow chart of study design Supplementary Figure 2. Quantile-quantile plot of stage 1 results QQ plot of the observed -log10 P-values (y axis) versus the

More information

On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles

On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles On the Reproducibility of TCGA Ovarian Cancer MicroRNA Profiles Ying-Wooi Wan 1,2,4, Claire M. Mach 2,3, Genevera I. Allen 1,7,8, Matthew L. Anderson 2,4,5 *, Zhandong Liu 1,5,6,7 * 1 Departments of Pediatrics

More information

Accelerate Your Research with Conversant Bio

Accelerate Your Research with Conversant Bio Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely

More information

Set the stage: Genomics technology. Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands

Set the stage: Genomics technology. Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands Set the stage: Genomics technology Jos Kleinjans Dept of Toxicogenomics Maastricht University, the Netherlands Amendment to the latest consolidated version of the REACH legislation REACH Regulation 1907/2006:

More information

Supplementary information

Supplementary information Supplementary information Human Cytomegalovirus MicroRNA mir-us4-1 Inhibits CD8 + T Cell Response by Targeting ERAP1 Sungchul Kim, Sanghyun Lee, Jinwook Shin, Youngkyun Kim, Irini Evnouchidou, Donghyun

More information

Nature Neuroscience: doi: /nn Supplementary Figure 1

Nature Neuroscience: doi: /nn Supplementary Figure 1 Supplementary Figure 1 Illustration of the working of network-based SVM to confidently predict a new (and now confirmed) ASD gene. Gene CTNND2 s brain network neighborhood that enabled its prediction by

More information

Patient characteristics of training and validation set. Patient selection and inclusion overview can be found in Supp Data 9. Training set (103)

Patient characteristics of training and validation set. Patient selection and inclusion overview can be found in Supp Data 9. Training set (103) Roepman P, et al. An immune response enriched 72-gene prognostic profile for early stage Non-Small- Supplementary Data 1. Patient characteristics of training and validation set. Patient selection and inclusion

More information

omiras: MicroRNA regulation of gene expression

omiras: MicroRNA regulation of gene expression omiras: MicroRNA regulation of gene expression Sören Müller, Goethe University of Frankfurt am Main Molecular Bioinformatics Group, Institute of Computer Science Plant Molecular Biology Group, Institute

More information

Lentiviral Delivery of Combinatorial mirna Expression Constructs Provides Efficient Target Gene Repression.

Lentiviral Delivery of Combinatorial mirna Expression Constructs Provides Efficient Target Gene Repression. Supplementary Figure 1 Lentiviral Delivery of Combinatorial mirna Expression Constructs Provides Efficient Target Gene Repression. a, Design for lentiviral combinatorial mirna expression and sensor constructs.

More information

Review on Tumour Doubling Time (DT) To review the studies that measuring the actual tumour doubling time for human cancers.

Review on Tumour Doubling Time (DT) To review the studies that measuring the actual tumour doubling time for human cancers. Review on Tumour Doubling Time (DT) Objective To review the studies that measuring the actual tumour doubling time for human cancers. Methods We searched the Medline database from January 1966 to January

More information

GWAS of HCC Proposed Statistical Approach Mendelian Randomization and Mediation Analysis. Chris Amos Manal Hassan Lewis Roberts Donghui Li

GWAS of HCC Proposed Statistical Approach Mendelian Randomization and Mediation Analysis. Chris Amos Manal Hassan Lewis Roberts Donghui Li GWAS of HCC Proposed Statistical Approach Mendelian Randomization and Mediation Analysis Chris Amos Manal Hassan Lewis Roberts Donghui Li Overall Design of GWAS Study Aim 1 (DISCOVERY PHASE): To genotype

More information

Supplementary Figure S1A

Supplementary Figure S1A Supplementary Figure S1A-G. LocusZoom regional association plots for the seven new cross-cancer loci that were > 1 Mb from known index SNPs. Genes up to 500 kb on either side of each new index SNP are

More information

Diagnostic IHC in lung and pleura pathology

Diagnostic IHC in lung and pleura pathology Diagnostic IHC in lung and pleura pathology Mogens Vyberg Professor of Clinical Pathology Director of NordiQC Aalborg University Hospital, Aalborg, Denmark WHO 2004 and Web Malignant mesothelioma Epithelioid

More information

Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia

Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia Introduction Cancer is a major concern in FA patients. This chapter will describe the most common types of non-head and neck solid

More information

Cardiovascular. Diseases. a simple and standardized kit qpcr analysis of circulating platelet-derived micrornas

Cardiovascular. Diseases. a simple and standardized kit qpcr analysis of circulating platelet-derived micrornas microrna Biomarkers of Platelet Function Neurodegenerative Diseases Cardiovascular Diseases Musculoskeletal Diseases a simple and standardized kit qpcr analysis of circulating platelet-derived micrornas

More information

BIMM 143. RNA sequencing overview. Genome Informatics II. Barry Grant. Lecture In vivo. In vitro.

BIMM 143. RNA sequencing overview. Genome Informatics II. Barry Grant. Lecture In vivo. In vitro. RNA sequencing overview BIMM 143 Genome Informatics II Lecture 14 Barry Grant http://thegrantlab.org/bimm143 In vivo In vitro In silico ( control) Goal: RNA quantification, transcript discovery, variant

More information

List of Available TMAs in the PRN

List of Available TMAs in the PRN TMA RPCI_BrainCa01 RPCI_BrCa03 RPCI_BrCa04 RPCI_BrCa05 RPCI_BrCa0 RPCI_BrCa07 RPCI_BrCa08 RPCI_BrCa15 RPCI_BrCa1 RPCI_BrCa17 RPCI_BrCa18 RPCI_BrCa19 RPCI_BrCa20 RPCI_BrCa21 RPCI_BrCa24 RPCI_BrCa25 RPCI_BrCa2

More information

Table S2. Baseline characteristics of the Rotterdam Study for interaction analysis

Table S2. Baseline characteristics of the Rotterdam Study for interaction analysis Supplementary data Table S1. List of the primers for the cloning of precursor mir-4707 Table S2. Baseline characteristics of the Rotterdam Study for interaction analysis Table S3. List of the primers for

More information

Expert-guided Visual Exploration (EVE) for patient stratification. Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland

Expert-guided Visual Exploration (EVE) for patient stratification. Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland Expert-guided Visual Exploration (EVE) for patient stratification Hamid Bolouri, Lue-Ping Zhao, Eric C. Holland Oncoscape.sttrcancer.org Paul Lisa Ken Jenny Desert Eric The challenge Given - patient clinical

More information

Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries

Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries Advances in Brain Tumor Research: Leveraging BIG data for BIG discoveries Jill Barnholtz-Sloan, PhD Associate Professor & Associate Director for Bioinformatics and Translational Informatics jsb42@case.edu

More information

UK Biobank. Death and Cancer Outcomes Report. September

UK Biobank. Death and Cancer Outcomes Report. September UK Biobank Death and Cancer Outcomes Report September 2016 http://www.ukbiobank.ac.uk/ 1 Contents 1. Introduction...... 2 2. Data on deaths Figure 2.1: Numbers of the 20 most common causes of death.........

More information

mir-509-5p and mir-1243 increase the sensitivity to gemcitabine by inhibiting

mir-509-5p and mir-1243 increase the sensitivity to gemcitabine by inhibiting mir-509-5p and mir-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer Hidekazu Hiramoto, M.D. 1,3, Tomoki Muramatsu, Ph.D. 1, Daisuke Ichikawa,

More information

The Cancer Genome Atlas

The Cancer Genome Atlas The Cancer Genome Atlas July 14, 2011 Kenna M. Shaw, Ph.D. Deputy Director The Cancer Genome Atlas Program TCGA: Core Objectives Launched in 2006 as a pilot and expanded in 2009, the goals of TCGA are

More information

ABSTRACT INTRODUCTION

ABSTRACT INTRODUCTION /, Vol. 5, No. 19 What makes a blood cell based mirna expression pattern disease specific? - A mirnome analysis of blood cell subsets in lung patients and healthy controls Petra Leidinger 1,*, Christina

More information

micro-rnas as biomarkers in children who underwent surgery for CHD

micro-rnas as biomarkers in children who underwent surgery for CHD micro-rnas as biomarkers in children who underwent surgery for CHD mentors: Dr. Yael Nevo-Caspi & Prof. Gidi Paret Or Bercovich Liat Mor What will we talk about Congenital heart defects (CHD) Scientific

More information

Expanded View Figures

Expanded View Figures Molecular Systems iology Tumor CNs reflect metabolic selection Nicholas Graham et al Expanded View Figures Human primary tumors CN CN characterization by unsupervised PC Human Signature Human Signature

More information

April 5, :45 AM 1:45 PM MARRIOTT MARQUIS HOTEL & MARINA, MIRAMAR VIGNETTE 1 VIGNETTE 2 VIGNETTE 3* VIGNETTE 4* VIGNETTE 5*

April 5, :45 AM 1:45 PM MARRIOTT MARQUIS HOTEL & MARINA, MIRAMAR VIGNETTE 1 VIGNETTE 2 VIGNETTE 3* VIGNETTE 4* VIGNETTE 5* April 5, 2016 11:45 AM 1:45 PM MARRIOTT MARQUIS HOTEL & MARINA, MIRAMAR CHAIR: DANNY A. MILNER, JR., BRIGHAM & WOMEN S HOSPITAL, BOSTON, MA VIGNETTE 1 VIGNETTE 2 VIGNETTE 3* VIGNETTE 4* VIGNETTE 5* *VIGNETTES

More information

Duskova et al. BMC Infectious Diseases 2013, 13:250

Duskova et al. BMC Infectious Diseases 2013, 13:250 Duskova et al. BMC Infectious Diseases 2013, 13:250 RESEARCH ARTICLE Open Access MicroRNA regulation and its effects on cellular transcriptome in Human Immunodeficiency Virus-1 (HIV-1) infected individuals

More information

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies

OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies OncoPPi Portal A Cancer Protein Interaction Network to Inform Therapeutic Strategies 2017 Contents Datasets... 2 Protein-protein interaction dataset... 2 Set of known PPIs... 3 Domain-domain interactions...

More information